糖脉交泰胶囊对高糖高脂糖尿病大鼠糖脂代谢及肝脏葡萄糖激酶、低密度脂蛋白受体的影响

目的研究糖脉交泰胶囊对高糖高脂糖尿病大鼠糖脂代谢及肝脏葡萄糖激酶(GCK)、低密度脂蛋白受体(LDLR)蛋白表达的影响。方法高糖高脂饮食加小剂量链脲佐菌素(STZ,35 mg.kg-1)联合诱导制备高糖高脂糖尿病大鼠模型,并随机分组为正常对照组、模型组、糖脉交泰组和吡格列酮组,每组8只,给予相应的药物治疗4周。实验结束后比较各组空腹血糖值(FBG)、糖化血清蛋白(GSP)、糖化血红蛋白(HbA1c)、血清总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)及肝糖原等指标;Western blot法检测肝脏组织中GCK和LDLR蛋白表达。结果与模型组比较,糖脉交泰胶囊能明显降低大鼠FBG、HbA1c、GSP水平,明显改善TC、TG、LDL-C等指标(P<0.05);肝脏肝糖原含量及LDLR和GCK的蛋白表达均明显增加(P<0.05)。结论糖脉交泰胶囊具有明显的调节糖脂代谢的作用,其作用机制与其提高肝糖原的含量,增加肝脏GCK和LDLR蛋白表达相关联。

Effect of TangMaiJiaoTai on regulating the glycolipid metabolism and the production of glucokinase and low density lipoprotein receptor protein in diabetic rats with hyperlipidemia

Aim To investigate the effect of TangMaiJiaoTai on regulating glycolipid metabolism and the production of glucokinase(GCK) and low density lipoprotein receptor(LDLR) protein in diabetic rats with hyperlipidemia.Methods Streptozotocin(STZ)-induced diabetic rats were developed with multiple low-dose STZ(35 mg·kg-1) injection and high-fat and sugar diet.The rats were randomly divided into normal,model,TMJT and pioglitazone groups(n=8).Each group was given the corresponding treatment for 4 weeks.The fasting blood glucose(FBG),glycosylated serum protein(GSP),glycosylated hemoglobin(HbA1c),serum total cholesterol(TC),triglycerides(TG),low-density lipoprotein(LDL-C),high-density lipoprotein(HDL-C) and liver glycogen were measured by the commercially available kits.Meanwhile,Western blot assay was applied to detect the protein expression of GCK and LDLR.Results TangMaiJiaoTai significantly attenuated the abnormal increase of FBG,GSP,HbA1c and improved the level of TC,TG,LDL-C and HDL-C in serum of STZ-induced diabetic rats(P<0.05).Furthermore,the liver glycogen content and protein expression of GCK and LDLR in liver were markedly increased in diabetic rats after TangMaiJiaoTai treatment(P<0.05).Conclusions TangMaiJiaoTai has obvious effect on regulating the disturbance of glycolipid metabolism.The function of TangMaiJiaoTai is relevant to its role of improving the content of liver glycogen and protein levels of GCK and LDLR.